pharmacotherapy for opioid use disorder

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

At 7-12 months postpartum, opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment, suggesting the protective effect of pharmacotherapy waned in the

Effect: null; 12.3 per 100,000 person-days (overall rate at 7-12 months postpartum); CI: 95% CI 9.9-15.0

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C

Women receiving pharmacotherapy with methadone or buprenorphine had statistically significantly lower opioid overdose rates compared to women not receiving pharmacotherapy at 4-6 months postpartum (1.

Effect: improvement; 1.3 per 100,000 person-days on pharmacotherapy vs 10.7 per 100,000 person-days not on pharmacotherapy at 4-6 months postpartum; CI: 95% C